A randomized, double-blind, placebo-controlled trial with mannan-conjugated birch pollen allergoids

Area of Science:

• Immunology
• Allergology
• Pharmacology

Background:

• Allergen immunotherapies (AIT) require improved efficacy and safety.
• Mannan-conjugated allergoids represent a novel strategy for AIT.
• Birch pollen-induced allergic rhinoconjunctivitis necessitates effective short-course treatments.

Purpose of the Study:

• To determine the optimal dose of mannan-conjugated birch pollen allergoids for short-course treatment.
• To evaluate the efficacy of different doses in patients with allergic rhinoconjunctivitis.
• To assess the safety and immunologic effects of the investigational treatment.

Main Methods:

• A prospective, randomized, double-blind, placebo-controlled, dose-finding study.
• 246 adults with birch pollen allergy received placebo or varying doses of mannan-conjugated birch pollen allergoids.
• Efficacy measured by symptom and medication scores; immunologic, safety, and tolerability analyzed.

Main Results:

• The highest dose (10,000 mTU/mL) significantly reduced combined symptom and medication scores by 24.7% compared to placebo.
• A dose-dependent increase in Bet v 1 specific IgG4 and a significant reduction in the IgE/IgG4 ratio were observed.
• All doses were deemed safe, with no serious adverse events reported.

Conclusions:

• Mannan-conjugated birch pollen allergoids are safe for treating allergic rhinoconjunctivitis.
• The 10,000 mTU/mL dose demonstrated the highest efficacy and warrants further investigation.
• This approach shows potential for effective short-course allergen immunotherapy.